Clinical Study

Alliance A021703- Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer

Posted Date: Feb 27, 2020

  • Investigator: Tahir Latif
  • Specialties: Cancer, Colorectal Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is To compare the progression-free survival (PFS) of patients receiving high-dose vitamin D3 in ombination with standard chemotherapy (FOLFOX or FOLFIRI) and bevacizumab versus hose receiving standard-dose vitamin D3 in combination with standard chemotherapy and bevacizumab


To Be Eligible: Must Have Advanced/Metastatic Colorectal Adenocarcinoma, Measureable Disease, Ecog 0-1, No Prior Treatment For Study Cancer, No Resectable Disease, No History Of Chf, Hypercalcemia, Or Other Active Uncontrolled Concurrent Illness Or Infection


Colorectal Cancer, Colon, Oncology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.